New pill could cut heart risk for those with stubborn high lp(a)
NCT ID NCT06816264
First seen Nov 17, 2025 · Last updated May 20, 2026 · Updated 25 times
Summary
This study tested an oral medication, HRS-5346, in 120 adults with high levels of lipoprotein(a) — a genetic risk factor for heart attacks and strokes. Participants were at high cardiovascular risk and received either the drug or a placebo. The main goal was to see if the drug safely lowers Lp(a) levels in the blood.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TREATMENT OF LIPOPROTEIN DISORDER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Peking University Third Hospital
Beijing, Beijing Municipality, 100000, China
Conditions
Explore the condition pages connected to this study.